Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arterial Line

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    134 result(s) found for: Arterial Line. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2010-023988-17 Sponsor Protocol Number: 260777 Start Date*: 2014-04-04
    Sponsor Name:BrepCo Biopharma Limited
    Full Title: Management of Hypotension In the Preterm: A multi centre, randomised, controlled trial of hypotension management in the extremely low gestational age newborn
    Medical condition: Low Blood Pressure
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10024895 Low blood pressure LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-000874-19 Sponsor Protocol Number: 1235.21 Start Date*: 2008-11-19
    Sponsor Name:Boehringer Ingelheim Pharmaceuticals. Inc.
    Full Title: A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg...
    Medical condition: type 2 diabetes and mild to moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011150-17 Sponsor Protocol Number: AMB112565 Start Date*: 2010-08-26
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary arterial hypotension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed) SE (Completed) GB (Completed) AT (Completed) GR (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002078-19 Sponsor Protocol Number: AC-055-405 Start Date*: 2015-10-14
    Sponsor Name:ACTELION Pharmaceuticals France
    Full Title: Prospective, multicenter, open-label study evaluating the effects of first-line oral combination therapy of macitentan and tadalafil in patients with newly diagnosed pulmonary arterial hypertension.
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003776-13 Sponsor Protocol Number: ALN-AGT01-003 Start Date*: 2021-12-15
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled b...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Ongoing) LT (Ongoing) LV (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000873-40 Sponsor Protocol Number: 1235.20 Start Date*: 2009-01-27
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como tera...
    Medical condition: Hipertensión grave Severe Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) CZ (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001248-82 Sponsor Protocol Number: ALN-AGT01-002 Start Date*: 2022-10-14
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007711-32 Sponsor Protocol Number: 502.550 Start Date*: 2009-07-15
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A randomised, double-blind, double dummy, active controlled, parallel group, forced titration study to compare the fixed-dose combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ...
    Medical condition: Severe Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-003909-26 Sponsor Protocol Number: BOP-TCI-001 Start Date*: 2014-02-04
    Sponsor Name:UMCG
    Full Title: Bayesian optimized Propofol Target-Controlled Infusion
    Medical condition: Patients requiring general anaesthesia for surgery using propofol and requiring an arterial line for invasive blood pressure monitoring as part of their clinical care.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003607-17 Sponsor Protocol Number: Rasmusscell Start Date*: 2023-01-12
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa
    Full Title: Phase I, open-label clinical trial to evaluate the safety and clinical response of repeated-dose intra-arterial infusion of autologous mesenchymal cells in children and adolescents with refractory ...
    Medical condition: Autoimmune refractory epilepsy and Rasmussen Encephalitis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000230-53 Sponsor Protocol Number: TMC-CLV-07-02 Start Date*: 2008-05-15
    Sponsor Name:The Medicines Company
    Full Title: The evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment
    Medical condition: Acute hypertension in patients who present with intracerebral hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022754 Intracerebral hemorrhage LLT
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005381-19 Sponsor Protocol Number: KIT-302-03-01 Start Date*: 2014-05-16
    Sponsor Name:Kitov Pharmaceuticals Ltd
    Full Title: A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000098-21 Sponsor Protocol Number: TDE-PH-311 Start Date*: 2012-11-06
    Sponsor Name:United Therapeutics Corporation
    Full Title: An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) AT (Completed) FR (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002779-64 Sponsor Protocol Number: DAP-PEDS-09-01 Start Date*: 2015-06-29
    Sponsor Name:Cubist Pharmaceuticals, Inc.
    Full Title: An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic T...
    Medical condition: Gram Positive Bacterial Infection
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002214-47 Sponsor Protocol Number: KIT-302-03-02 Start Date*: 2016-10-04
    Sponsor Name:Kitov Pharmaceuticals Ltd
    Full Title: A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects with Existing Hypertension ...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004106-87 Sponsor Protocol Number: CAS CVVH Start Date*: 2007-10-23
    Sponsor Name:Meical University, Dpt. Internal Medicine, Div. of General Internal Medicine
    Full Title: CLINICAL PHARMACOKINETICS OF CASPOFUNGIN IN CRITICALLY ILL PATIENTS DURING CONTINUOUS VENO-VENOUS HEMOFILTRATION
    Medical condition: Plasma concentrations of Caspofungin will be measured in patients requiring treatment with Cancidas (Caspofungin) and continuous veno-venous hemofiltration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004526-33 Sponsor Protocol Number: PDARCT1 Start Date*: Information not available in EudraCT
    Sponsor Name:Royal College of Surgeons in Ireland
    Full Title: A Randomised Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score
    Medical condition: Patent Ductus Arteriosus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10034130 Patent ductus arteriosus PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002826-58 Sponsor Protocol Number: 1 Start Date*: 2020-02-05
    Sponsor Name:Rijnstate Hospital, Arnhem
    Full Title: The effects of enoximone in acute exacerbation COPD: a pilot study
    Medical condition: Acute exacerbation of COPD
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003194-24 Sponsor Protocol Number: CPI-226-03 Start Date*: 2006-01-02
    Sponsor Name:Cadence Pharmaceuticals, Inc.
    Full Title: Estudio en fase III, multicéntrico, aleatorizado, con enmascaramiento del tratamiento para el comité de evaluación para valorar la eficacia de la administración tópica de omiganán al 1,0% en gel en...
    Medical condition: Prevención de infecciones en la zona del catéter. Prevention of local site infections in patients requiring central venous and/or arterial catheterization and/or peripherally inserted central veno...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002330-23 Sponsor Protocol Number: 9794 Start Date*: 2017-11-24
    Sponsor Name:University hospital of Montpellier
    Full Title: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY
    Medical condition: The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036706 Primary liver cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA